RxDoctor Payments Data

Matthew Stawarz, NP

Family · Abingdon, VANPI 1376231548

Payments from drug & device makers

$3,413in general payments, 2019–2025

Across 172 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$603
  • Novartis$562
  • E.r. Squibb & Sons, L.L.C.$536
  • Novo Nordisk$336
  • Johnson & Johnson$210
  • Merck$197
  • plus $971 from 11 others

What the payments were for

  • Food & beverage$3,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,413 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$64,727
Medicare patients
406
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$106,356
EntrestoSacubitril/Valsartan94$97,526
JardianceEmpagliflozin94$88,094
BrilintaTicagrelor48$34,348
XareltoRivaroxaban32$27,726
Ranolazine ErRanolazine63$4,000
Metoprolol Succinate216$2,199
Valsartan64$1,348
Carvedilol171$1,016
ClopidogrelClopidogrel Bisulfate152$924
Isosorbide Mononitrate ErIsosorbide Mononitrate120$834
Rosuvastatin Calcium96$734
Nitroglycerin52$716
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$711
Metoprolol Tartrate143$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$562$97,52694 claims
Boehringer IngelheimJardiance$157$88,09494 claims
AstraZenecaBrilinta$603$34,34848 claims
Johnson & JohnsonXarelto$210$27,72632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →